Guanfacine (Tenex)

Subscribe to Selected New Research on Guanfacine

205 relevant articles (29 outcomes, 36 trials/studies) found for this Drug

Description: A centrally acting antihypertensive agent. The drug lowers both systolic and diastolic blood pressure by activating the central nervous system alpha-2 adrenoreceptors, which results in reduced sympathetic outflow leading to reduced vascular tone. Its adverse reactions include dry mouth, sedation, and constipation.

Also Known As:

Tenex; BS-100-141; Estulic; Guanfacine Hydrochloride; Guanfacine Monohydrochloride; Lon798; BS 100 141; BS100141; Hydrochloride, Guanfacine; Monohydrochloride, Guanfacine; Benzeneacetamide, N-(aminoiminomethyl)-2,6-dichloro-

Relationship Network

Drug Context: Research Results

Organic Chemicals: 40

Experts

1.	Lyne, Andrew: 2 articles (01/2008 - 09/2007)
2.	Siever, Larry J: 2 articles (05/2007 - 01/2003)
3.	Swartz, Barbara E: 1 article (09/2008)
4.	Torgersen, Denise: 1 article (09/2008)
5.	Patel, Ashok: 1 article (09/2008)
6.	McDonald, Carrie R: 1 article (09/2008)
7.	Hardan, Antonio Y: 1 article (08/2008)
8.	Handen, Benjamin L: 1 article (08/2008)
9.	Sahl, Robert: 1 article (08/2008)
10.	Ward, Charles: 1 article (01/2008)

Related Diseases

1.	Hypertension (High Blood Pressure) 08/01/1982 - "This study demonstrated the efficacy of guanfacine monotherapy in hypertension and suggests that the normalization rate of blood pressure levels does not further increase with daily doses higher than 4 mg." 01/01/1991 - "Estulic tablet proved to be effective in form of monotherapy especially in the treatment of mild hypertension, in form of combination therapy in hypertension of medium severity" 01/01/1989 - "Guanfacine monotherapy was effective in 75% of patients with moderate hypertension (using low doses 1-3 mg/day)" 01/01/1981 - "It is considered that guanfacine is a useful new antihypertensive drug, effective in mild hypertension, and side-effects are few if doses are maintained below 3 mg daily" 07/01/1982 - "Efficacy of guanfacine in the treatment of arterial hypertension]" Get all the results and reference details, order at left...
2.	Attention Deficit Disorder with Hyperactivity (Attention Deficit Hyperactivity Disorder) 01/01/2008 - "All groups of children taking guanfacine extended release showed significant improvement on hyperactivity/impulsivity and inattentiveness subscales of the Attention-Deficit/Hyperactivity Disorder Rating Scale IV, Clinical Global Impression of Improvement, Parent's Global Assessment, Conners' Parent Rating Scale-Revised: Short Form, and Conners' Teacher Rating Scale-Revised: Short Form assessments compared with placebo" 09/01/2007 - "BACKGROUND: Guanfacine hydrochloride is an alpha(2a)-adrenoreceptor agonist found to be effective in the treatment of attention-deficit/hyperactivity disorder (ADHD)" 10/01/2002 - "The alpha2-AR agonist guanfacine enhances prefrontal cortical functions in rats, monkeys, and human beings and ameliorates prefrontal cortical deficits in patients with attention deficit hyperactivity disorder" 01/01/2008 - "OBJECTIVE: With this study we assessed the efficacy and safety of an extended-release formulation of guanfacine compared with placebo for the treatment of children and adolescents with attention-deficit/hyperactivity disorder" 01/01/2008 - "A randomized, double-blind, placebo-controlled study of guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder." Get all the results and reference details, order at left...
3.	Renal Insufficiency 03/28/1986 - "Based on pharmacokinetic studies in these target groups and on the dual renal and nonrenal clearance of guanfacine, the drug may, most probably, be administered to elderly patients and patients with renal insufficiency without dosage adjustment." 01/01/1989 - "The steady-state pharmacokinetics and renal clearance of guanfacine were studied in patients with renal insufficiency" 01/01/1980 - "Pharmacokinetic study of guanfacine in patients with renal insufficiency and in patients under chronic dialysis (author's transl)]" 01/01/1989 - "Higher plasma levels of guanfacine were observed in patients with GFR less than 30 ml/min. The steady state t 1/2 of guanfacine in the presence of renal insufficiency was insignificantly prolonged relative to that observed in the presence of normal renal function and appeared to be independent of the degree of renal insufficiency." 01/01/1989 - "Steady-state plasma levels and pharmacokinetics of guanfacine in patients with renal insufficiency." Get all the results and reference details, order at left...
4.	Tic Disorders (Tic Disorder) 07/01/2001 - "CONCLUSIONS: Guanfacine appears to be a safe and effective treatment for children with tic disorders and ADHD." 11/01/2005 - "CONCLUSION: Results of this open-label study add to the growing data base on the safety and efficacy of guanfacine in children with ADHD and tic disorders." 11/01/2005 - "An open-label, prospective study of guanfacine in children with ADHD and tic disorders." 07/01/2001 - "METHOD: Subjects from a specialty tic disorders clinic were randomly assigned to receive 8 weeks of treatment with guanfacine or placebo under double-blind conditions" 07/01/2001 - "OBJECTIVE: This study evaluated the efficacy and safety of guanfacine in treating children with tic disorders and attention deficit hyperactivity disorder (ADHD)" Get all the results and reference details, order at left...
5.	Memory Disorders (Memory Loss) 09/01/2001 - "Guanfacine has demonstrated efficacy in reversing working memory deficits in non-human primate" 01/01/2008 - "The data suggest a possible hierarchy of specificity in the current medications used in the treatment of ADHD, with guanfacine likely to be most specific for the treatment of prefrontal attentional and working memory deficits" 11/01/1988 - "The ability of low doses of guanfacine to improve memory without inducing hypotension or sedation indicates that this agonist may be an excellent candidate for treating memory disorders in man." 11/01/2000 - "The present study examined the alpha-2 adrenoceptor subtype underlying this reversal in FG7142-induced working memory deficits by comparing the efficacy of clonidine with the more selective alpha-2A adrenoceptor agonist, guanfacine" Get all the results and reference details, order at left...
70 Diseases and 205 more articles analyzed in the Research Interface, order at left...

Related Drugs and Biologics

1.	Clonidine (ST 155)
2.	Methyldopa (Aldomet)
3.	Growth Hormone (Somatotropin)
4.	Aldosterone
5.	Dextroamphetamine (Dexedrine)
6.	Xylazine (Xylazin)
7.	Prazosin (Minipress)
8.	Tetrabenazine (Nitoman)
9.	Pergolide (Permax)
10.	Methadone (Dolophine)
90 Drugs and Important Bio-Agents and 113 more articles analyzed in the Research Interface, order at left...

Related Therapies and Procedures

1.	Drug Therapy (Chemotherapy)
2.	Exercise (Aerobic Exercise)
3.	Ligation
4.	Induced Hypothermia
5.	Denervation
7 Therapies and Procedures and 8 more articles analyzed in the Research Interface, order at left...

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License details >>

Price:

$490.00 access via web interface, 1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m", 1 year subscription

Proceed to Checkout >>